The estimated Net Worth of Karen Bernstein is at least 95.5 千$ dollars as of 16 February 2023. Karen Bernstein owns over 8,750 units of Ovid Therapeutics Inc stock worth over 9,800$ and over the last 7 years he sold OVID stock worth over 0$. In addition, he makes 85,714$ as Independent Director at Ovid Therapeutics Inc.
Sign up
Karen Bernstein OVID stock SEC Form 4 insiders trading
Karen has made over 3 trades of the Ovid Therapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 8,750 units of OVID stock worth 9,800$ on 16 February 2023.
The largest trade he's ever made was buying 10,000 units of Ovid Therapeutics Inc stock on 26 February 2019 worth over 20,200$. On average, Karen trades about 1,513 units every 87 days since 2017. As of 16 February 2023 he still owns at least 8,750 units of Ovid Therapeutics Inc stock.
You can see the complete history of Karen Bernstein stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Karen Bernstein biography
Dr. Karen Bernstein Ph.D. serves as Independent Director of the Company. Dr. Bernstein co-founded BioCentury Inc., or BioCentury, a provider of clinical, regulatory and finance news for the biotechnology and pharmaceutical industries, where she served as Editor-in-Chief from its inception in August 1992 to August 2015. Dr. Bernstein currently serves on the board of directors of Achaogen, Inc., a publicly held biopharmaceutical company. She previously served on the board of directors of Vitae Pharmaceuticals, Inc., which was acquired by Allergan Holdco US, Inc. Dr. Bernstein continues to serve as Chairman of the board of director BioCentury, Inc. Dr. Bernstein earned her BA in Politics and History from Brandeis University and her PhD in Political Science from Stanford University. Bernstein’s extensive knowledge of the life science industry qualifies her to serve on our Board.
What is the salary of Karen Bernstein?
As the Independent Director of Ovid Therapeutics Inc, the total compensation of Karen Bernstein at Ovid Therapeutics Inc is 85,714$. There are 8 executives at Ovid Therapeutics Inc getting paid more, with Jeremy Levin having the highest compensation of 3,008,980$.
How old is Karen Bernstein?
Karen Bernstein is 67, he's been the Independent Director of Ovid Therapeutics Inc since 2015. There are 3 older and 12 younger executives at Ovid Therapeutics Inc. The oldest executive at Ovid Therapeutics Inc is Bart Friedman, 75, who is the Lead Independent Director.
What's Karen Bernstein's mailing address?
Karen's mailing address filed with the SEC is C/O OVID THERAPEUTICS INC., 441 NINTH AVENUE, NEW YORK, NY, 10001.
Insiders trading at Ovid Therapeutics Inc
Over the last 9 years, insiders at Ovid Therapeutics Inc have traded over 37,290$ worth of Ovid Therapeutics Inc stock and bought 2,202,070 units worth 5,624,523$ . The most active insiders traders include Pharmaceutical Co Ltdmillen...、Barbara Gayle Duncan、Jeremy M Levin. On average, Ovid Therapeutics Inc executives and independent directors trade stock every 218 days with the average trade being worth of 229,440$. The most recent stock trade was executed by Jeremy M Levin on 18 March 2024, trading 18,248 units of OVID stock currently worth 50,364$.
What does Ovid Therapeutics Inc do?
ovid therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. ovid’s drug candidate, ov101, is currently in development for the treatment of symptoms of angelman syndrome and fragile x syndrome. ovid is also developing ov935 in collaboration with takeda pharmaceutical company limited for the treatment of rare epileptic encephalopathies. ovid has initiated the phase 2 stars trial of ov101 in adults with angelman syndrome and a phase 1 trial in adolescents with angelman and fragile x syndrome to identify doses suitable for younger patients. review our community guidelines: http://www.ovidrx.com/community-guidelines/
What does Ovid Therapeutics Inc's logo look like?
Complete history of Karen Bernstein stock trades at Ovid Therapeutics Inc、Codiak BioSciences
Ovid Therapeutics Inc executives and stock owners
Ovid Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Jeremy Levin,
Chairman of the Board, Chief Executive Officer -
Amit Rakhit,
President, Chief Medical Officer -
Dirk Haasner,
Senior Vice President - Global Regulatory Affairs -
Timothy Daly,
Executive Vice President - Finance, Corporate Controller, Treasurer -
Dr. Jeremy Max Levin Ba Zoology, Dphil, Mb Bchir,
Pres, CEO & Chairman -
Thomas Michael Perone J.D., M.B.A.,
Gen. Counsel, Chief Compliance Officer & Corp. Sec. -
Jeffrey A. Rona,
Principal Financial Officer, Principal Accounting Officer & Chief Bus. and Financial Officer -
Bart Friedman,
Lead Independent Director -
Douglas Williams,
Independent Director -
Karen Bernstein,
Independent Director -
Barbara Duncan,
Independent Director -
Jason Tardio,
Chief Commercial Officer -
Thomas Perone,
Chief Compliance Officer, General Counsel, Corporate Secretary -
Luke Rosen,
Sr. VP of Accelerated Devel. & Community Engagement -
Dr. Claude Nicaise,
Head of R&D -
Dr. Dirk Haasner,
Sr. VP of Global Manufacturing & CMC QA -
Suzanne K. Wakamoto SHRM-SCP, SPHR,
Sr. VP of HR -
Lora Pike,
Sr. Director of Investor Relations & PR -
Jason Tardio M.B.A.,
Chief Commercial Officer & COO -
Dr. Matthew J. During Ph.D., M.D., DSc, FACP, FRACP,
Founder & Member of Scientific Advisory Board -
Matthew During,
Director -
Yaron Werber,
CBO, CFO, Sec. and Treas. -
Pharmaceutical Co Ltdmillen...,
-
Ana Ward,
SVP and General Counsel -
Robert Michael Poole,
Director -
Pharmaceutical Co Ltd Taked...,
-
Kevin Joseph Fitzgerald,
Director -
Margaret A. Alexander,
President and COO -
Jeffrey A Rona,
CBFO